Microprolactinomas in males treated by transsphenoidal surgery
- PMID: 14628197
- DOI: 10.1007/s00701-003-0134-y
Microprolactinomas in males treated by transsphenoidal surgery
Abstract
Objective: To support the opinion that transsphenoidal surgery can be an effective alternative to medical treatment for microprolactinomas in men.
Design: Clinical study with retrospective data analysis.
Patients and methods: Of 46 men who were operated on for prolactinoma in the Department of Neurosurgery of the University of Vienna General Hospital between 1985 and 2000 a microadenoma was detected 11 times (24%).
Results: Median patient age was 41 years (range 32 to 54 years). Symptoms were of endocrine nature in all patients with erectile dysfunction, infertility and gynaecomastia being the initial complaints and having lasted for a median of 13 months (range 7-68 months). Preoperative median serum prolactin (PRL) was elevated to 120 ng/ml (range 41-1000 ng/ml). Radiography by MRI revealed microadenomas with a median diameter of 8 mm (range 4-10 mm). All patients were operated on via the transsphenoidal approach. Endocrine cure as defined by a serum PRL <25 ng/ml was achieved in 8 of 11 patients (73%) after a median follow-up of 7 years (range 2-13 years). In none of the 3 patients with preoperative serum PRL levels >150 ng/ml was a normoprolactinaemia obtained after surgery: 2 require further dopamine-agonist therapy after surgery, 1 after late follow-up. Surgery and medical treatment could restore potency and libido in all but 1 patient, 2 of 3 patients remain infertile.
Conclusion: Prolactinomas in males are potentially curable by surgery if detected at an early stage. They most commonly present with insidious signs and symptoms of endocrine disturbances such as loss of libido, impotence and sterility. We stress the importance of early determination of serum prolactin and high resolution magnetic resonance tomography of the sella in male patients with hyperprolactinaemia as this may prevent the possible progression to larger tumours which are rarely curable by surgery and necessitate life-long medical therapy.
Similar articles
-
Use of the Leksell gamma knife in the treatment of prolactinoma patients.Clin Endocrinol (Oxf). 2009 May;70(5):732-41. doi: 10.1111/j.1365-2265.2008.03384.x. Epub 2008 Aug 15. Clin Endocrinol (Oxf). 2009. PMID: 18710463
-
Surgery, dopamine agonist therapy of combined treatment--results in prolactinoma patients after a 12 month follow-up.Zentralbl Neurochir. 1992;53(3):123-34. Zentralbl Neurochir. 1992. PMID: 1414079
-
Endocrinological outcome following first time transsphenoidal surgery for GH-, ACTH-, and PRL-secreting pituitary adenomas.Acta Neurochir (Wien). 2002 Jun;144(6):555-61; discussion 561. doi: 10.1007/s00701-002-0938-1. Acta Neurochir (Wien). 2002. PMID: 12111488
-
The use of surgery for the treatment of prolactinomas.Acta Endocrinol (Copenh). 1993 Jul;129 Suppl 1:34-7. Acta Endocrinol (Copenh). 1993. PMID: 8103958 Review.
-
Transsphenoidal hypophysectomy: a critical review.Trans Pa Acad Ophthalmol Otolaryngol. 1990;42:1002-7. Trans Pa Acad Ophthalmol Otolaryngol. 1990. PMID: 2084974 Review.
Cited by
-
Endoscopic endonasal surgery for prolactinomas: prognostic factors for disease control and management of persistent disease.Neurosurg Rev. 2023 Nov 9;46(1):295. doi: 10.1007/s10143-023-02199-7. Neurosurg Rev. 2023. PMID: 37940745
-
Hyperprolactinemia and male sexual function: focus on erectile dysfunction and sexual desire.Int J Impot Res. 2024 Jun;36(4):324-332. doi: 10.1038/s41443-023-00717-1. Epub 2023 Jun 20. Int J Impot Res. 2024. PMID: 37340146 Review.
-
Treatment of hyperprolactinemia: a systematic review and meta-analysis.Syst Rev. 2012 Jul 24;1:33. doi: 10.1186/2046-4053-1-33. Syst Rev. 2012. PMID: 22828169 Free PMC article.
-
Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis.Chin Neurosurg J. 2022 Apr 8;8(1):9. doi: 10.1186/s41016-022-00277-1. Chin Neurosurg J. 2022. PMID: 35395837 Free PMC article.
-
Prolactinomas in males: any differences?Pituitary. 2020 Feb;23(1):52-57. doi: 10.1007/s11102-019-01009-y. Pituitary. 2020. PMID: 31802331 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical